Lupin plans expansion, aims to enter Chinese market in the next one year

The company has now decided to focus on specialty drugs. The annual price cuts made the Japanese generics market unattractive

Mumbai-headquartered Lupin is firming up plans to enter the Chinese market in the next one year. Its peers Sun Pharmaceuticals and Dr Reddy’s Laboratories (DRL) already have a presence in the dragon nation. 

Nilesh Gupta, managing director of Lupin, confirmed that the firm was keen to enter China.

“In fact, last March, a management team was scheduled to visit China to explore prospects. This, however, could not happen due to the pandemic. We were planning to enter the market in 2021, but it got delayed due to the pandemic,” Gupta said. He feels the Chinese market has great potential for respiratory drugs